Literature DB >> 23277285

Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Rosa Filiberti1, Paola Marroni, Manlio Mencoboni, Virginia Mortara, Pietro Caruso, Alex Cioè, Luigi Michelazzi, Domenico F Merlo, Andrea Bruzzone, Barbara Bobbio, Lisette Del Corso, Roberto Galli, Paola Taveggia, Guglielmo Dini, Fabio Spigno.   

Abstract

The soluble mesothelin-related peptide (SMRP), a candidate marker for screening of subjects with asbestos exposure, is influenced by some individual and clinical factors. The aim of this study was to quantify the role of age, smoking, weight, presence of diseases and exposure to asbestos on serum SMRP levels in a large series of subjects exposed to asbestos, possible candidates for mesothelioma screening. One thousand seven hundred and four participants underwent clinical examination and were interviewed on medical anamnesis, occupation, smoking and weight. SMRP was measured by an ELISA assay. Overall, median SMRP was 0.4 (IQR 25-75: 0.3-0.7) nmol/l. It was higher in current smokers and in subjects with a cumulative asbestos exposure >50 ff/cc/years than in all the other subjects (p < 0.001 and p = 0.002, respectively). SMRP was positively correlated with age (ρ = 0.11, p < 0.001) and, inversely, with BMI (ρ = -0.15, p < 0.001). SMRP was lower in healthy subjects (n = 1,217: median 0.4 nmol/l) than in subjects with malignant tumors (n = 118: 0.5 nmol/l; p = 0.01), asbestos-related pleural lesions (plaques or thickenings, n = 152: 0.6 nmol/l; p < 0.001) and other benign diseases (n = 182: 0.5 nmol/l; p = 0.04). Multivariate analysis revealed significant predictors of increased SMRP: age >57 years, current smoking, a positive anamnesis for cancer and for asbestos-related pleural lesions, and BMI < 25. Some clinical and demographic variables are associated with serum SMRP levels. The degree of these associations is low, nevertheless they should be accounted for in the interpretation of SMPR as a candidate marker predictive of mesothelioma. The potential predictive value of serum SMRP in screening/surveillance programs must be validated in prospective studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277285     DOI: 10.1007/s12032-012-0422-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

1.  Overweight adults may have the lowest mortality--do they have the best health?

Authors:  Anna Zajacova; Jennifer Beam Dowd; Sarah A Burgard
Journal:  Am J Epidemiol       Date:  2011-01-12       Impact factor: 4.897

2.  Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.

Authors:  Jenette Creaney; Nola J Olsen; Fraser Brims; Ian M Dick; Arthur W Musk; Nicholas H de Klerk; Steven J Skates; Bruce W S Robinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-22       Impact factor: 4.254

Review 3.  Tobacco, inflammation, and respiratory tract cancer.

Authors:  Javier Milara; Julio Cortijo
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Authors:  Harvey I Pass; Anil Wali; Naimei Tang; Alla Ivanova; Sergey Ivanov; Michael Harbut; Michele Carbone; Jeffrey Allard
Journal:  Ann Thorac Surg       Date:  2008-01       Impact factor: 4.330

Review 5.  Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.

Authors:  Ling Luo; Huan-Zhong Shi; Qiu-Li Liang; Jing Jiang; Shou-Ming Qin; Jing-Min Deng
Journal:  Respir Med       Date:  2009-11-30       Impact factor: 3.415

6.  Effect of smoking on pleural thickening in asbestos workers.

Authors:  E Yano; K Tanaka; M Funaki; K Maeda; C Matsunaga; K Yamaoka
Journal:  Br J Ind Med       Date:  1993-10

7.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

8.  Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk.

Authors:  Monica Amati; Marco Tomasetti; Laura Mariotti; Lucia Miria Tarquini; Matteo Valentino; Lory Santarelli
Journal:  Mutat Res       Date:  2008 Aug-Sep       Impact factor: 2.433

9.  Radiographic small lung opacities and pleural abnormalities in relation to smoking, urbanization status, and occupational asbestos exposure in Finland.

Authors:  A J Zitting; A Karjalainen; O Impivaara; T Kuusela; J Mäki; A Tossavainen; J Järvisalo
Journal:  J Occup Environ Med       Date:  1996-06       Impact factor: 2.162

Review 10.  Statistics review 6: Nonparametric methods.

Authors:  Elise Whitley; Jonathan Ball
Journal:  Crit Care       Date:  2002-09-13       Impact factor: 9.097

View more
  4 in total

Review 1.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

Authors:  Michele Carbone; Harvey I Pass; Guntulu Ak; H Richard Alexander; Paul Baas; Francine Baumann; Andrew M Blakely; Raphael Bueno; Aleksandra Bzura; Giuseppe Cardillo; Jane E Churpek; Irma Dianzani; Assunta De Rienzo; Mitsuru Emi; Salih Emri; Emanuela Felley-Bosco; Dean A Fennell; Raja M Flores; Federica Grosso; Nicholas K Hayward; Mary Hesdorffer; Chuong D Hoang; Peter A Johansson; Hedy L Kindler; Muaiad Kittaneh; Thomas Krausz; Aaron Mansfield; Muzaffer Metintas; Michael Minaai; Luciano Mutti; Maartje Nielsen; Kenneth O'Byrne; Isabelle Opitz; Sandra Pastorino; Francesca Pentimalli; Marc de Perrot; Antonia Pritchard; Robert Taylor Ripley; Bruce Robinson; Valerie Rusch; Emanuela Taioli; Yasutaka Takinishi; Mika Tanji; Anne S Tsao; A Murat Tuncer; Sebastian Walpole; Andrea Wolf; Haining Yang; Yoshie Yoshikawa; Alicia Zolondick; David S Schrump; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2022-04-21       Impact factor: 20.121

3.  Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals.

Authors:  Hsiao-Yu Yang
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

4.  Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.

Authors:  Katja Goricar; Viljem Kovac; Metoda Dodic-Fikfak; Vita Dolzan; Alenka Franko
Journal:  Radiol Oncol       Date:  2020-03-07       Impact factor: 2.991

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.